Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Copan announces leadership transition in medical and scientific affairs

September 2025—Copan Diagnostics has appointed Hema Kapoor, MD, D(ABMM), as director of medical and scientific affairs for the Americas, succeeding Susan Sharp, PhD, D(ABMM), who will retire this month following more than three decades of distinguished service to clinical microbiology. Dr. Sharp joined Copan in 2018, after a career spanning more than 30 years as a clinical microbiologist, educator, and industry leader. She previously served as chief of microbiology at Kaiser Permanente and held leadership roles at the American Society for Microbiology, including chair of the committee on laboratory practices and past president. A diplomate of the American Board of Medical Microbiology and fellow of the American Academy of Microbiology, Dr. Sharp has been recognized with ASM’s highest clinical honor, the BioMérieux Sonnenwirth Award, and the ABMM Professional Recognition Award. At Copan, her leadership has been defined by keen insight and a steadfast advocacy for advancing microbiology.

Labcorp, NowDx collaborate to expand rapid syphilis testing

September 2025—Labcorp and NowDiagnostics are collaborating to expand access to rapid syphilis testing. The companies will distribute First to Know Syphilis Test kits at no cost to select community-based public health organizations across the United States. Labcorp and NowDx distributed kits to more than 15 organizations across the country, including to LGBTQ+ health centers, HIV/AIDS care providers, and safety-net clinics. Labcorp serves as the exclusive commercial laboratory offering the test for health care providers as well as directly to consumers

SehaMed, New Day Dx to launch ColoHealth in the Middle East

September 2025—SehaMed Global (Bristol, England) announced a strategic distribution agreement with New Day Diagnostics of Knoxville, Tenn., to bring ColoHealth, an FDA-approved blood test for the early detection of colorectal cancer, to patients in Saudi Arabia, the United Arab Emirates, and other countries in the Middle East. Under the terms of the agreement, SehaMed will leverage its network of distributors across the Gulf Cooperation Council to introduce ColoHealth.

Vizgen, Hamamatsu partner to streamline spatial biology workflows

August 2025—Vizgen and Hamamatsu Photonics have entered a strategic partnership that integrates Hamamatsu’s MoxiePlex multiplex immunofluorescence imaging system with Vizgen’s reagent and assay portfolio. The companies plan to combine their expertise through validated In­SituPlex panels, coupled with MoxiePlex, as an integrated multiplexed proteomic biomarker offering capable of multisite deployments for translational and clinical research applications.

IDT unveils infectious disease research solutions

August 2025—Integrated DNA Technologies has unveiled its PrimeTime influenza kit and PrimeTime research pathogen panels. The influenza kit is a qPCR solution designed to amplify common influenza strains and targets influenza A, influenza A (H5N1), influenza B, and RNase. It includes an internal control for sample quality assessment, a premixed primer and probe set, PrimeTime 4x Broad-Range Master Mix, and direct amplification enhancer.

MRC Holland assay for Peutz-Jeghers gains EU IVDR certification

August 2025—MRC Holland announced that its Salsa MLPA Probemix P101 STK11 assay for the detection of Peutz-Jeghers syndrome received the CE mark for in vitro diagnostic use under IVDR regulation EU 2017/746. The probe mix detects copy number variations in the STK11 gene and has been updated with two improved and two newly added denaturation control probes that facilitate the detection of denaturation issues with exceptional sensitivity, according to a company press statement.

SSI Diagnostica acquires Gulf Coast Scientific

August 2025—SSI Diagnostica Group is acquiring Gulf Coast Scientific (Oldsmar, Fla.), which specializes in the development of urea breath testing for Helicobacter pylori, to further strengthen its gastrointestinal disease testing portfolio. SSI Diagnostica, headquartered in Denmark, acquired CTK Biotech (Poway, Calif.) in 2020 and TechLab (Blacksburg, Va.) in 2022. Jointly the group will have a total revenue of approximately $125 million.

Waters acquires Halo Labs

August 2025—Waters Corp. announced it has acquired Halo Labs. Halo Labs’ Aura platform, which features a highly differentiated technology that performs full spectrum particle analysis, is complementary to the Waters light-scattering detection solutions from its Wyatt Technology portfolio. The subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T cells for cell therapy. By acquiring Halo Labs, Waters said it will be able to integrate the emerging technology into new and existing large molecule development and QA/QC.

Randox unveils Evidence RABTA

August 2025—Randox has launched the Evidence RABTA (random access biochip technology analyzer), capable of processing up to 60 samples per hour and delivering up to 2,640 test results per hour. The analyzer offers seamless random access capabilities, allows users to assign samples as priority, and uses single-use tips for aspiration and dispensing. The time to first result is 36 minutes, with up to 44 results per sample. Walkaway time is up to 2.5 hours.

CytoChip showcases CLIA-waived CitoCBC at ADLM

August 2025—CytoChip showcased its flagship product, CitoCBC, a cartridge-based CBC analyzer, at the Association for Diagnostics and Laboratory Medicine annual meeting, July 27–31, in Chicago. CitoCBC delivers rapid CBC results with a five-part white blood cell differential from a cartridge-based system and requires only monthly quality control.

MARKETPLACE

TRENDING